Sickle cell-beta+ thalassaemia in Orissa State, India
- PMID: 2004023
- DOI: 10.1111/j.1365-2141.1991.tb07980.x
Sickle cell-beta+ thalassaemia in Orissa State, India
Abstract
The clinical, haematological, and some molecular genetic features of 17 Orissan Indian patients with sickle cell-beta+ thalassaemia (S beta+ thal) are described and compared with those in 131 Indian patients with homozygous sickle cell (SS) disease. Patients with S beta+ thal had higher Hb A2 levels, and lower mean cell volume (MCV) and mean cell haemoglobin (MCH) compared to SS disease but no other haematological difference of statistical significance. High levels of Hb F occurred in both genotypes and the alpha+ thalassaemia gene frequency reached 0.47 in S beta+ thal and 0.32 in SS disease. Clinically there were no significant differences between the genotypes indicating that the low levels of HbA (3-5%) in this condition were insufficient to modify the clinical features. The thalassaemic beta globin gene is inactivated by a G----C mutation at position 5 of the first intron of the beta globin gene (IVS1-5 G----C) in all cases. This finding should facilitate the introduction of a prenatal diagnosis programme aimed at the prevention of beta thalassaemia or S beta+ thalassaemia in that population.
Similar articles
-
A comparison of sickle cell syndromes in northern Greece.Br J Haematol. 1991 Mar;77(3):386-91. doi: 10.1111/j.1365-2141.1991.tb08589.x. Br J Haematol. 1991. PMID: 2012764
-
Comparison of sickle cell-beta0 thalassaemia with homozygous sickle cell disease.Br J Haematol. 1979 Jan;41(1):83-93. doi: 10.1111/j.1365-2141.1979.tb03684.x. Br J Haematol. 1979. PMID: 420738
-
Sickle cell-beta 0-thalassaemia in Saudi Arabia.Hum Hered. 1987;37(4):211-6. doi: 10.1159/000153705. Hum Hered. 1987. PMID: 2443440
-
Sickle cell disease in India.Curr Opin Hematol. 2002 Mar;9(2):117-22. doi: 10.1097/00062752-200203000-00006. Curr Opin Hematol. 2002. PMID: 11844994 Review.
-
Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease.Adv Exp Med Biol. 2017;1013:59-87. doi: 10.1007/978-1-4939-7299-9_3. Adv Exp Med Biol. 2017. PMID: 29127677 Free PMC article. Review.
Cited by
-
Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease.Eur J Haematol. 2025 Feb;114(2):293-302. doi: 10.1111/ejh.14323. Epub 2024 Oct 29. Eur J Haematol. 2025. PMID: 39473076 Free PMC article. Clinical Trial.
-
Coinheritance of B-Thalassemia and Sickle Cell Anaemia in Southwestern Nigeria.Ethiop J Health Sci. 2016 Nov;26(6):517-522. doi: 10.4314/ejhs.v26i6.3. Ethiop J Health Sci. 2016. PMID: 28450766 Free PMC article.
-
Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics.Hemoglobin. 2020 Jan;44(1):1-9. doi: 10.1080/03630269.2020.1731530. Epub 2020 Mar 16. Hemoglobin. 2020. PMID: 32172616 Free PMC article.
-
Sickle cell disease in tribal populations in India.Indian J Med Res. 2015 May;141(5):509-15. doi: 10.4103/0971-5916.159492. Indian J Med Res. 2015. PMID: 26139766 Free PMC article.
-
Clinical, hematologic and molecular variability of sickle cell-β thalassemia in western India.Indian J Hum Genet. 2010 Sep;16(3):154-8. doi: 10.4103/0971-6866.73410. Indian J Hum Genet. 2010. PMID: 21206704 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous